Slaughter and May is advising GlaxoSmithKline plc in relation to its €453 million acquisition of two injectable anti-thrombotic agents, Fraxiparine and Arixtra, and a French manufacturing facility from Sanofi-Synthélabo. The acquisition was announced on 13 April 2004 and completion is conditional upon the closing of Sanofi-Synthélabo’s public offer for Aventis and receipt of requisite competition clearances.
Slaughter and May is advising GlaxoSmithKline plc in relation to its …
